Published in Yonsei Med J on December 31, 2006
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Viral hepatitis C. Lancet (2003) 5.81
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med (1992) 3.01
Modeling the hepatitis C virus epidemic in France. Hepatology (1999) 1.61
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet (2001) 1.52
Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology (2004) 1.30
Introduction to therapy of hepatitis C. Hepatology (2002) 1.26
Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat (1999) 1.06
Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma. J Korean Med Sci (1998) 0.99
Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology (2000) 0.92
The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer (2000) 0.91
Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. J Viral Hepat (2003) 0.82
The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncol Rep (1998) 0.79
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Intrahepatic cholangiocarcinoma with predominant "ductal plate malformation" pattern: a new subtype. Am J Surg Pathol (2012) 2.25
Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans. Hepatology (2011) 2.25
Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2002) 2.18
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol (2008) 2.03
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology (2011) 1.87
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology (2007) 1.81
Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int (2007) 1.80
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology (2008) 1.78
Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol (2004) 1.77
Biliary atresia: color doppler US findings in neonates and infants. Radiology (2009) 1.70
[Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea]. Korean J Hepatol (2008) 1.70
Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology (2011) 1.67
Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res (2012) 1.67
Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab (2012) 1.65
The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol (2012) 1.63
Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology (2009) 1.60
DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med (2007) 1.59
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys (2003) 1.56
Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol (2008) 1.55
Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics (2009) 1.55
Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Am J Gastroenterol (2006) 1.48
[Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol (2009) 1.48
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol (2012) 1.46
Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. Liver Int (2010) 1.46
Variability in liver stiffness values from different intercostal spaces. Liver Int (2009) 1.45
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One (2012) 1.43
MRI features of hepatocellular carcinoma expressing progenitor cell markers. Liver Int (2011) 1.42
Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol (2004) 1.39
Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int (2005) 1.37
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer (2008) 1.36
Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci (2008) 1.35
Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol (2008) 1.34
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2007) 1.33
Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol (2005) 1.33
Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer (2012) 1.32
Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol (2010) 1.30
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology (2011) 1.29
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int (2013) 1.27
Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg (2009) 1.26
HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther (2011) 1.26